Rajiv Amesur, DO
Pulmonary Disease · Henderson, NVNPI 1538422183
Payments from drug & device makers
What this record shows
This record is dominated by education: $5,577 of the $8,709 with a category attached, or 64.0%. Intuitive Surgical accounts for 84.1% of it on its own, with 12 other manufacturers making up the rest.
Across 34 payments — averaging $256.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Olympus Corporation Of The Americas$656
- Actelion Pharmaceuticals US, Inc.$194
- Penumbra, Inc.$137
- Veran Medical Technologies, Inc.$108
- Olympus America Inc.$61
- plus $231 from 7 others
What the payments were for
- Travel & lodging$1,86721%
- Food & beverage$1,26515%
- Education$5,57764%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $7,322 |
| Olympus Corporation Of The Americas | 6 | $656 |
| Actelion Pharmaceuticals US, Inc. | 2 | $194 |
| Penumbra, Inc. | 1 | $137 |
| Veran Medical Technologies, Inc. | 1 | $108 |
| Olympus America Inc. | 1 | $61 |
| Fujifilm Healthcare Americas Corporation | 1 | $59 |
| Verona Pharma, Inc. | 2 | $49 |
| GSK | 3 | $43 |
| Tactile Systems Technology Inc | 1 | $25 |
| AstraZeneca | 1 | $20 |
| Baxter Healthcare | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,709 in reported general payments places this provider in the 75th percentile of 84 pulmonary disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 198 | $194,935 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 125 | $102,921 |
| Breo ElliptaFluticasone/Vilanterol | 61 | $34,452 |
| EliquisApixaban | 33 | $20,327 |
| Spiriva RespimatTiotropium Bromide | 29 | $18,091 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 71 | $8,649 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $6,748 |
| Wixela InhubFluticasone Propion/Salmeterol | 48 | $6,143 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 257 | $5,493 |
| Roflumilast | 23 | $4,112 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 39 | $2,170 |
| Sildenafil Citrate | 19 | $1,207 |
| Mycophenolate Mofetil | 13 | $683 |
| Montelukast Sodium | 32 | $663 |
| Prednisone | 89 | $545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $43 | $236,134273 claims |
| AstraZenecaBreztri Aerosphere | $20 | $102,921125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 84 pulmonary disease providers in Nevada.
Other pulmonary disease in Henderson
- Cyriac ChemplavilHenderson$18K
- Thomson ChemplavilHenderson$17K
- Sapna BhatiaHenderson$10K
- Robert WillsHenderson$8K
- Syed AkbarullahHenderson$4K
- Michelle DanielianHenderson$2K
- Xenia SchneiderHenderson$805
- Hrishikesh KulkarniHenderson$606
- Kenneth MooneyHenderson$500
- James HsuHenderson$461
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.